Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and to determine the proportion of patients who need new antiretroviral drugs with minimal cross-resistance.
Introduction
Surveillance of HIV resistance ongoing in France for .10 years 1,2 in treated patients with detectable viral load (VL) is important to assess the risk of spread of resistant viruses and to determine the proportion of patients needing new drugs. Our aims were to describe mutations associated with virological failure (VF) in 2014 and to compare them with those found in a similar survey conducted in 2009. We also evaluated genotyping success rate according to plasma VL.
Patients and methods

Study population and data collection
This prospective, multicentre, cross-sectional study enrolled HIV-1-infected patients receiving combination ART (cART) for at least 6 months with two consecutive VL values of .50 copies/mL between September and December 2014. Sociodemographic and clinical data, treatment history and regimen at the time of VF, and HIV-1 resistance sequencing data were collected.
Ethics
The study was approved by an ethics committee (Comite Consultatif de Traitement de l'Information dans la Recherche Scientifique et Medicale) and by the national data confidentiality watchdog organization (Commission Nationale Informatique et Libertes), in keeping with French law. The patients received full information on their participation in the study and did not oppose the use of their data.
Genotypic resistance analysis
Protease, reverse transcriptase and integrase gene mutations were identified from the International AIDS Society resistance testing USA panel (version July 2014). Genotyping results were interpreted with the ANRS algorithm (2014, version 24) . We considered that a virus was resistant to a drug when it was ranked 'resistant' or 'possibly resistant' to the drug.
Statistical analysis
Rates of successful sequencing and resistance were calculated according to plasma HIV RNA levels (51-200, 201-500, 501-1000 and .1000 copies/mL). Univariate and multivariable logistic regression models were used to identify factors predictive of the risk of amplification failure. Weighted analyses, based on number of patients from each centre, were used to derive representative estimates of percentages of patients harbouring viruses with resistanceassociated mutations (RAMs). Virus was considered resistant to a class of drugs when ranked 'resistant' to all drugs in the class. We used the FHDH ANRS CO4 cohort dataset to estimate the percentage of treated patients with VL .50 copies/mL, who could potentially transmit resistant viruses.
Sequences from our previous 2009 survey 2 were re-analysed concomitantly to compare frequencies of RAMs between the two surveys. Multivariable logistic regression analysis was used to study the impact of period adjusted for factors that differed significantly between the two surveys.
Results
Characteristics of the study population
We included 782 patients in 37 centres. Protease and reverse transcriptase genes were successfully amplified in 566 (72.4%) patients. Amplification of integrase was successful in 382 of 480 cases.
The characteristics of the study population are summarized in Table 1 . Patients were exposed to a median of 6 antiretroviral drugs (IQR 3-9), including 2 NRTIs (IQR 0-4), 1 NNRTI (IQR 0-1), 3 PIs (IQR 2-4) and 0 INIs (IQR 0-1). Ten percent were on first-line treatment.
Genotyping success rate
Success of resistance genotyping was 72.4% overall, and 87%, 78%, 78% and 60% for samples with VL .1000, 501-1000, 201-500 and 51-200 copies/mL, respectively. Multivariable analysis showed that risk of unsuccessful resistance genotyping was 4.7-fold higher (95% CI 3.0-7.2, P , 0.001) and 1.8-fold higher (95% CI 1.0-3.2, P " 0.040) when VL was 51-200 and 201-500 copies/mL, respectively, than when it was .1000 copies/mL. This risk was 2.5-fold higher (95% CI 1.7-3.5, P , 0.001) in cases of non-B subtype.
Genotypic resistance patterns
The most commonly observed NRTI RAMs were M184V/I (25.9%), and the most common thymidine analogue mutations were M41L, D67N, K70R, L210W, T215Y/F and K219Q/E (5.7%-13.5%). K65R and L74V were present in 2.1% and 3.6% of samples, respectively. The most frequent NNRTI RAMs were K103N (12.6%), Y181C (10.7%) and E138A/K (8.2%). Prevalence of major PI resistance mutations ranged from 0.2% (G48V) to 12.5% (V82A/F/M/S/T). The most common INI RAMs were N155H (5.2%), Q148H (2.9%), E157Q (3.4%) and G140S (2.4%). Q148H/R/K was preferentially associated with G140S (1.4%). R263K mutation was observed in 0.5% of samples.
Drug resistance interpretation
Resistance to at least one antiretroviral drug was observed in 56.3% of samples (at least one NRTI in 36.0%, NNRTI in 32.1%, PI in 20.2% and INI in 12.0%), and was less frequent in first-line treatment failure than in patients with multiple failures (42.1% versus 57.9%, P " 0.025). Percentages of viruses not susceptible to any antiretroviral drugs in the NRTI, NNRTI, PI and INI classes were 3.5%, 9.2%, 1.6% and 3.4%, respectively. Frequency of resistance Assoumou et al. to all members of at least one drug class was 13.4%. Resistance to all drugs in one, two, three and four antiretroviral drug classes was 11.1%, 1.2%, 0.8% and 0.3%, respectively.
In France in 2014, 90.0% of patients were receiving antiretroviral drugs and 12.0% of them had detectable VL. Therefore, although 56.3% of treated patients with detectable VL harboured viruses with resistance to at least one antiretroviral drug, extrapolation to the entire French database suggests that only 6.7% of treated patients would be at risk of transmitting resistant viruses.
Drug resistance according to VL
Resistance to at least one drug rose significantly with plasma VL (P , 0.001) (Figure 1 ). Resistance to at least one NRTI was more frequent at .200 copies/mL than at 51-200 copies/mL (38.9% versus 30.1%, P " 0.036), while this was not observed with other classes.
Comparison between 2009 and 2014 studies
VL at the time of VF was significantly lower in 2014 than in 2009 (P , 0.001) ( Table 1) .
Resistance was less prevalent in 2014 than in 2009. Multivariable analysis showed that the decrease in resistance rates was not influenced by factors that differed significantly between the two surveys (adjusted OR " 1.6, 95% CI 1.2-2.1, P " 0.005). This decline was not significant for nevirapine (P " 0.051) or efavirenz (P " 0.080). Prevalence of resistance to rilpivirine was higher in 2014 than in 2009 (20% versus 16%, P " 0.020) and stable for etravirine (12% versus 9%, P " 0.166).
Resistance to at least one drug was significantly less frequent in 2014 than in 2009 at the VL levels of 501-1000 copies/mL (61.0% versus 78.1%, P " 0.039) and .1000 copies/mL (57.8% versus 69.5%, P " 0.009). No difference was observed at VL levels of 51-200 and 201-500 copies/mL (Figure 1 ).
Discussion
We evaluated prevalence of RAMs among a large number of patients experiencing VF. Genotyping success was 72% overall, compared with 67% in the previous 2009 survey (P " 0.023).
2 This improvement was noteworthy among patients with low VL (,200 copies/mL: 34% versus 60%, P , 0.001) and might be due to more efficient amplification, as genotyping procedure changed between the two surveys. Our findings agree with those of another recent study. 3 Nevertheless, our multivariable analysis showed that low VL remains associated with amplification failure, together with non-B subtype viruses and confirmed limits of genotyping for non-B strains. 4 Prevalence of RAMs fell significantly between the two surveys, whereas frequency of mutations E138A/K and H221Y conferring resistance to new-generation NNRTIs increased significantly, probably because of widespread use of these drugs. Mutation K103N was observed in 12.6% of patients, similar to the 2009 survey, despite less use of first-generation NNRTIs in 2014. High prevalence of K103N might be due to NNRTI past exposure but might also occur because the replicative capacity of viruses harbouring this mutation is almost preserved. 5, 6 To date, there is no other nationwide survey of HIV-1 resistance in patients with VF in other countries since our 2009 survey. Resistance to at least one antiretroviral drug was detected in 56.3% of samples, which is in keeping with another study. 
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Prevalence of resistance to at least one antiretroviral drug was high (48.5%) among patients with low-level viraemia (LLV) of ,200 copies/mL. Several studies have shown that LLV can promote the selection of resistance mutations. [8] [9] [10] Similar results to those obtained in our study showed that 50% of patients with LLV had viruses with RAMs. 3, 11 We found that prevalence of resistance to at least one PI, NNRTI or INI did not differ between patients with VL ,200 copies/mL and those with VL .200 copies/mL. This supports the idea that genotyping must be attempted for all regimens, including those with low genetic barrier.
We found that resistance was less prevalent in 2014 than in 2009, except for next-generation NNRTIs. This decline may be explained by a reduction in use of older NNRTIs with a low genetic barrier. At the time of VF, 6.5% of patients were receiving etravirine in 2009, compared with 10.8% of patients in 2014 (P " 0.012); corresponding figures for rilpivirine were 0% and 7.4% (P , 0.001).
By contrast, among patients with LLV, we found no difference in resistance rates between 2009 and 2014 when stratifying on VL categories. This strongly supports guidelines recommending resistance monitoring for all treated patients with VL .50 copies/mL, even though low VL remains a risk factor for unsuccessful sequencing.
One limitation of this study is the lack of cumulative genotyping, which might underestimate the prevalence of resistance. Furthermore, the observed decline in prevalence of resistance between 2009 and 2014 is based on separate cross-sectional surveys of two different populations. Despite the lack of adherence data, 75% of patients had low VL (,1000 copies/mL), suggesting adherence to therapy.
In conclusion, in 2014, in France, 6.7% of treated patients might possibly transmit resistant strains, close to the percentage observed in naive patients. 12, 13 Resistance was less prevalent than in 2009 except for new-generation NNRTIs. Our main findings are that resistance testing is feasible in most patients with VL ,200 copies/mL and that resistance is evidenced in 50% of cases in patients with plasma VL ,200 copies/mL. Therefore, resistance testing may be warranted, and largely feasible, in all treated patients with VL .50 copies/mL, challenging the definition of therapeutic failure in some current guidelines. Assoumou et al.
